J&J Outshines ABBV as Top Dividend Aristocrat for Retirees

Two pharmaceutical giants, AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ), are among the most stable dividend payers in their industry. Both companies have a long history of annual dividend increases, but one faces a patent cliff that may threaten its future earnings.

AbbVie's second-quarter revenue rose 10.2% to $16.99 billion, driven by strong sales of Skyrizi and Rinvoq, two immunology drugs. However, Humira, another key product, saw a significant decline in sales due to increased competition from biosimilars.

Johnson & Johnson, on the other hand, grew second-quarter sales 5.6% operationally to $25.3 billion, with 28 products and platforms generating over $1 billion annually. The company's diverse portfolio and robust balance sheet make it a more reliable choice for retirees who depend on dividend income.

While AbbVie is currently cheaper than Johnson & Johnson, its growth trajectory may be threatened by the patent expiration of Skyrizi in 2033. In contrast, J&J's AAA credit rating and strong free cash flow position make it a more stable investment choice for long-term investors.